ARO-RAGE
Nucleic acidexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 29, 2022 (NCT05276570)
Timeline
Indications
Studied for
Mechanism of action
- Advanced glycosylation end product-specific receptorANTISENSE INHIBITOR
AGER antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07241546 | Phase 2 | Dec 31, 2025 | Arrowhead Pharmaceuticals |
| NCT05533294 | Phase 1 | Nov 29, 2022 | Arrowhead Pharmaceuticals |
| NCT05276570 | Phase 1 | Jun 29, 2022 | Arrowhead Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | For profit | 3 | 3 | 2 | 2022 |
1 organizations
Page 1 / 1